ENDRA Life Sciences to Report Second Quarter 2022 Financial Results on August 15, 2022
August 04 2022 - 8:00AM
Business Wire
ENDRA Life Sciences Inc. (ENDRA) (NASDAQ: NDRA), a pioneer of
enhanced ultrasound technologies, today announced that the company
will report financial results for the second quarter of 2022 on
Monday, August 15, 2022 after the close of trading on the U.S.
financial markets. Management will host a conference call and
webcast beginning at 4:30 p.m. Eastern time to discuss the results,
provide an update on recent corporate developments and answer
questions.
Participants are encouraged to pre-register for the conference
call using this link. Callers who pre-register will be given a
unique PIN to gain immediate access to the call and bypass the live
operator. Participants may register at any time, including up to
and after the call start time. Those unable to pre-register may
participate by dialing (844) 868-8846 (U.S.) or (412) 317-5465
(International). A webcast of the call may also be accessed at
ENDRA’s Investor Relations page and here.
A telephone replay will be available until August 22, 2022 by
dialing (877) 344-7529 (U.S.) or (412) 317-0088 (International) and
providing the passcode 1237055. A webcast replay will be available
beginning approximately one hour after the completion of the live
conference call here.
About ENDRA Life Sciences Inc.
ENDRA Life Sciences is the pioneer of Thermo Acoustic Enhanced
UltraSound (TAEUS®), a ground-breaking technology being developed
to visualize tissue like MRI, but at 1/50th the cost and at the
point of patient care. TAEUS® is designed to work in concert with
over 500,000 ultrasound systems in use globally today. TAEUS® is
initially focused on the measurement of fat in the liver as a means
to assess and monitor Non-Alcoholic Fatty Liver Disease (NAFLD) and
Non-Alcoholic Steatohepatitis (NASH), chronic liver conditions that
affect over one billion people globally, and for which there are no
practical diagnostic tools. Beyond the liver, ENDRA is exploring
several other clinical applications of TAEUS®, including
visualization of tissue temperature during energy-based surgical
procedures. For more information, please visit
www.endrainc.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220804005007/en/
Company Contact: Irina Pestrikova Senior Director,
Finance investors@endrainc.com www.endrainc.com
Investor Relations Contact: Yvonne Briggs LHA Investor
Relations (310) 691-7100 ybriggs@lhai.com
ENDRA Life Sciences (NASDAQ:NDRA)
Historical Stock Chart
From Mar 2024 to Apr 2024
ENDRA Life Sciences (NASDAQ:NDRA)
Historical Stock Chart
From Apr 2023 to Apr 2024